Gaetan De Rauglaudre
Avignon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.
Journal: JCO precision oncology
Published: January 14, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.
Journal: Translational oncology
Published: September 29, 2025
Retraction Note: Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: February 06, 2025
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Journal: Gynecologic oncology
Published: November 21, 2022
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Journal: Gynecologic oncology
Published: October 03, 2022
Needs assessment for the establishment of an Oral Therapy Unit
Journal: Bulletin du cancer
Published: April 07, 2022
Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 20, 2020
Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 24, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 08, 2020
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 10, 2019
Last Updated: 09/26/2026